These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19170591)

  • 1. Daclizumab treatment for multiple sclerosis.
    Kim SE
    Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclizumab in treatment of multiple sclerosis patients.
    Ali EN; Healy BC; Stazzone LA; Brown BA; Weiner HL; Khoury SJ
    Mult Scler; 2009 Feb; 15(2):272-4. PubMed ID: 19136546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer in the treatment of multiple sclerosis.
    Rizvi SA; Kim E; Moodie J
    Int J Nanomedicine; 2006; 1(3):283-9. PubMed ID: 17717969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
    Martin R
    Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab use in patients with pediatric multiple sclerosis.
    Gorman MP; Tillema JM; Ciliax AM; Guttmann CR; Chitnis T
    Arch Neurol; 2012 Jan; 69(1):78-81. PubMed ID: 22232346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
    Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
    Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging multiple sclerosis oral therapies.
    Rammohan KW; Shoemaker J
    Neurology; 2010 Jan; 74 Suppl 1():S47-53. PubMed ID: 20038763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S
    Mt Sinai J Med; 2011; 78(2):192-206. PubMed ID: 21425264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowns and unknowns in the future of multiple sclerosis treatment.
    Stüve O
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.